<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03371888</url>
  </required_header>
  <id_info>
    <org_study_id>Silesian MU PRP</org_study_id>
    <nct_id>NCT03371888</nct_id>
  </id_info>
  <brief_title>The Platelet-Rich Plasma in the Therapy of Temporomandibular Disorders</brief_title>
  <acronym>PRP/TMD</acronym>
  <official_title>The Platelet -Rich Plasma in the Therapy of Temporomandibular Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Silesia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Silesia</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Platelet-Rich Plasma intramuscular injections into the masseter and temporalis muscle
      were performed to reduce painful temporomandibular disorder symptoms,such as myalgia,
      myofascial pain and myofascial pain with referrals. Patients(n=120) were randomly divided
      into two groups: experimental(n=60) and control group(n=60). In controls injections with 0,9%
      NaCl were performed. Pain intensity was measured with NPRS (numeriic pain rating scale, 0= no
      pain, 11= the worst pain that one can imagine) before(0 day), during(10 day) and after(20
      day) the therapy with PRP injections.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients(n=120) attending The Department of Temporomandibular Disorders and Orthodontics at
      the Silesian Medical University Poland, Zabrze were enrolled to the study and randomly
      divided into one of two groups: experimental and control group. Platelet-Rich Plasma(PRP) was
      prepared for each patient and an intramuscular injections of 0,5 ml PRP into 6 points at each
      side were performed in experimental group. A follow-up appointment was made after 10 and 20
      days and in each visit an injection of PRP or 0,9% NaCl was performed. Pain intensity was
      measured in NPRS(numeric pain rating scale) and collected data data were analyzed.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 7, 2017</start_date>
  <completion_date type="Actual">January 1, 2019</completion_date>
  <primary_completion_date type="Actual">December 15, 2018</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>An intervention performed in experimental group and control group</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
    <masking_description>double blinded study</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Pain intensity reduction in VAS scale,(VAS scale 0-10 points)</measure>
    <time_frame>14 days</time_frame>
    <description>Decrease in pain intensity in masseter and temporalis muscles.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">58</enrollment>
  <condition>PRP</condition>
  <condition>Temporomandibular Disorder</condition>
  <condition>Myalgia</condition>
  <condition>Bruxism</condition>
  <arm_group>
    <arm_group_label>PRP injections</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intramuscular injection of Platelet-Rich Plasma into the masseter and temporalis muscle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0,9% NaCl injections</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intramuscular injection of 0,9% NaCl into the masseter and temporalis muscle</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Platelet-Rich Plasma intramuscular injections</intervention_name>
    <description>A platelet-rich plasma intramuscular injections into the trigger points of painful muscles were performed.</description>
    <arm_group_label>PRP injections</arm_group_label>
    <other_name>PRP intramuscular injections</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo Comparator: 0,9% NaCl intramuscular injections</intervention_name>
    <description>A 0,9% NaCl intramuscular injections into the trigger points of painful muscles were performed.</description>
    <arm_group_label>0,9% NaCl injections</arm_group_label>
    <other_name>Saline intramuscular injections</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. presence of local myalgia, myofascial pain and myofascial pain with referral within
             masseter muscles according to the Diagnostic Criteria for Temporomandibular Disorders
             (DC/TMD) (II.1.A. 1, 2 and 3)

          2. patient's agreement for taking part into the research study

        Exclusion Criteria:

          1. patients being treated with or addicted to analgesic drugs and/or drugs that affect
             muscle function

          2. presence of contraindications for injection therapy

          3. patients being treated by neurologist for neurological disorders and/or neuropathic
             pain and/or headache

          4. patients after traumas to the head and neck region in the previous 2 years

          5. edentulous patients

          6. patients after radiotherapy

          7. presence of severe mental disorders

          8. pregnancy or lactation

          9. pain of dental origin

         10. presence of malignancy

         11. drug and/or alcohol addiction

         12. patients with needle phobia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>23 Years</minimum_age>
    <maximum_age>42 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aleksandra Nitecka-Buchta, DMD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Silesia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of TMD Silesian Medical University</name>
      <address>
        <city>Zabrze</city>
        <zip>41-800</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <reference>
    <citation>Wright EF, North SL. Management and treatment of temporomandibular disorders: a clinical perspective. J Man Manip Ther. 2009;17(4):247-54.</citation>
    <PMID>20140156</PMID>
  </reference>
  <reference>
    <citation>Xie X, Zhang C, Tuan RS. Biology of platelet-rich plasma and its clinical application in cartilage repair. Arthritis Res Ther. 2014 Feb 25;16(1):204. Review.</citation>
    <PMID>25164150</PMID>
  </reference>
  <reference>
    <citation>Amable PR, Carias RB, Teixeira MV, da Cruz Pacheco I, CorrÃªa do Amaral RJ, Granjeiro JM, Borojevic R. Platelet-rich plasma preparation for regenerative medicine: optimization and quantification of cytokines and growth factors. Stem Cell Res Ther. 2013 Jun 7;4(3):67. doi: 10.1186/scrt218.</citation>
    <PMID>23759113</PMID>
  </reference>
  <reference>
    <citation>Salamanna F, Veronesi F, Maglio M, Della Bella E, Sartori M, Fini M. New and emerging strategies in platelet-rich plasma application in musculoskeletal regenerative procedures: general overview on still open questions and outlook. Biomed Res Int. 2015;2015:846045. doi: 10.1155/2015/846045. Epub 2015 May 5. Review.</citation>
    <PMID>26075269</PMID>
  </reference>
  <reference>
    <citation>Stiles CD. The molecular biology of platelet-derived growth factor. Cell. 1983 Jul;33(3):653-5.</citation>
    <PMID>6307524</PMID>
  </reference>
  <reference>
    <citation>Pihut M, Ferendiuk E, Szewczyk M, Kasprzyk K, Wieckiewicz M. The efficiency of botulinum toxin type A for the treatment of masseter muscle pain in patients with temporomandibular joint dysfunction and tension-type headache. J Headache Pain. 2016;17:29. doi: 10.1186/s10194-016-0621-1. Epub 2016 Mar 24.</citation>
    <PMID>27011213</PMID>
  </reference>
  <reference>
    <citation>Tsai WC, Yu TY, Chang GJ, Lin LP, Lin MS, Pang JS. Platelet-Rich Plasma Releasate Promotes Regeneration and Decreases Inflammation and Apoptosis of Injured Skeletal Muscle. Am J Sports Med. 2018 Jul;46(8):1980-1986. doi: 10.1177/0363546518771076. Epub 2018 May 17.</citation>
    <PMID>29772187</PMID>
  </reference>
  <reference>
    <citation>Mazzocca AD, McCarthy MB, Chowaniec DM, Cote MP, Romeo AA, Bradley JP, Arciero RA, Beitzel K. Platelet-rich plasma differs according to preparation method and human variability. J Bone Joint Surg Am. 2012 Feb 15;94(4):308-16. doi: 10.2106/JBJS.K.00430.</citation>
    <PMID>22336969</PMID>
  </reference>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>December 7, 2017</study_first_submitted>
  <study_first_submitted_qc>December 7, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 13, 2017</study_first_posted>
  <last_update_submitted>January 2, 2019</last_update_submitted>
  <last_update_submitted_qc>January 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Silesia</investigator_affiliation>
    <investigator_full_name>Aleksandra Nitecka-Buchta</investigator_full_name>
    <investigator_title>DMD, PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Temporomandibular Joint Disorders</mesh_term>
    <mesh_term>Temporomandibular Joint Dysfunction Syndrome</mesh_term>
    <mesh_term>Myalgia</mesh_term>
    <mesh_term>Bruxism</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

